Price update of Jisandai (Bingtonsha) new drug for the treatment of hepatitis C in 2024

Epclusa (Epclusa), as a treatment drug for chronic hepatitis C, is a direct antiviral drug that can effectively combat hepatitis C virus (HCV). HCV can cause inflammation and damage to the liver, and in severe cases can lead to cirrhosis and even liver cancer.

Today, Jisandai (Bingtonsha) has been legally marketed in China and has been included in the medical insurance system, and patients can easily purchase it in China. Currently, the domestic pricing of this drug is roughly within the range of two to three thousand yuan. However, please note that the actual purchase price and medical insurance reimbursement policies may vary by region and hospital. Please consult the local hospital pharmacy for detailed consultation before purchasing.

In addition, Jisandai (Bingtonsa) and its generic drugs are also available in overseas markets, such as the versions produced in Bangladesh and India. The price is relatively low, ranging from a few hundred yuan to more than a thousand yuan, and its pharmaceutical ingredients are basically the same as the domestic original drugs.

Jisandai (Bingtonsa) is a prescription drug developed by a well-known American pharmaceutical company. It was officially approved for marketing by the U.S. Food and Drug Administration (FDA) in 2016. This drug is actually a compound preparation that mainly contains two active ingredients: Sofosbuvir (Sofosbuvir) and Velpatasvir (Velpatasvir). They inhibit the replication of HCV through different mechanisms of action, effectively reduce the viral load, and ultimately achieve the purpose of treating hepatitis C.

Compared with traditional treatment options, the advantages of Jisandai (Bingtonsha) are obvious. Its administration method is simple, and patients can take the medication orally at home for treatment, eliminating the need for hospitalization or frequent trips to the hospital. At the same time, the course of treatment is greatly shortened, usually only requiring 8-12 weeks of continuous use, while traditional treatment options may last as long as 24-48 weeks. More importantly, the efficacy of Jisanda (Bingtonsa) is remarkable. Most patients can achieve virological response after receiving treatment, that is, HCV RNA cannot be detected after treatment ends. This undoubtedly brings better efficacy and quality of life to patients.

Of course, Jisandai (Bingtonsha) may also cause some adverse reactions. Common ones include headache, fatigue, nausea, diarrhea and other digestive discomforts, including possible liver function abnormalities. Therefore, during the treatment of Jisandai (Bingtonsha), doctors will pay close attention to the patient's liver function and drug response in order to adjust the treatment plan in a timely manner.